SecBot SecBot
8-K ·Filed May 28, 2026

MNKD

MANNKIND CORP
BULLISH
Impact 6/10
Horizondays Processed5mo ago SEC0001193125-26-243074
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The FDA release from the pulmonary malignancy study is a clear positive catalyst, removing a long-standing regulatory overhang. The upcoming PDUFA date (May 29, 2026) for the pediatric sBLA adds near-term binary catalyst risk. Traders should watch for the pediatric decision as the next major event.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.64
T+0 close · May 28, 2026 · via day close
Latest settled
+14.01%
T+60 · $4.15
Vs SPY
+12.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $3.64entry
  2. T+1 · 6mo ago +3.57%α +3.33% · $3.77
  3. T+5 · 6mo ago −7.69%α −7.64% · $3.36
  4. T+20 · 5mo ago +13.74%α +16.88% · $4.14
  5. T+60 · 3mo ago +14.01%α +12.28% · $4.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind announced the FDA released it from a postmarketing requirement for Afrezza, a five-year pulmonary malignancy study in 8,000-10,000 type 2 diabetes patients, eliminating a major regulatory overhang. The only remaining postmarketing requirement is a pediatric efficacy/safety assessment, with a PDUFA target action date of May 29, 2026. Separately, the company provided a clinical update on the INHALE-1st pediatric study, with data expected in late 2027.

Key Facts

  • FDA released MannKind from a postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 Afrezza patients
  • Only remaining postmarketing requirement is pediatric efficacy/safety assessment (sBLA accepted October 2025, PDUFA date May 29, 2026)
  • INHALE-1st study: 8 additional sites activated, up to 100 participants expected, data expected late 2027

Financial Impact

Elimination of a costly, multi-year postmarketing study removes a significant future expense and regulatory risk; no dollar amount disclosed

regulatory riskfuture operating expenses

Risk Factors

  • PDUFA decision on pediatric sBLA (May 29, 2026) could result in a Complete Response Letter
  • INHALE-1st data not expected until late 2027, limiting near-term pipeline catalysts
  • No financial figures disclosed; cost savings from released postmarketing requirement are unquantified

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-243074
Document: 0001193125-26-243074-index-headers.html0001193125-26-243074
Document: 0001193125-26-243074-index.html0001193125-26-243074
Document: 0001193125-26-243074.txt0001193125-26-243074

Track record

17 reports on MNKD

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026